Company Overview
iBio, Inc. operates as a preclinical stage biotechnology entity focused on developing artificial intelligence-driven antibody solutions specifically tailored for the cardiometabolic and obesity therapeutic space. The company's technological portfolio includes platforms such as EngageTx, which offers an improved CD3 T-cell engager antibody panel, and ShieldTx, an antibody solution designed for specific clinical applications. As a public entity within the healthcare sector, the company functions within the broader biotechnology industry, a field characterized by high research and development costs and significant regulatory hurdles before products reach the market. The firm employs a workforce of 20 individuals and holds a market capitalization of $60.80M, while generating total revenue of $300,000 over the trailing twelve-month period. These financial figures indicate that the company is in an early-stage development phase where capital allocation is prioritized toward research rather than commercial sales, resulting in a market cap that reflects potential future value rather than current operational cash flow.
Financial Health
The company reported revenue of $300,000 for the trailing twelve months, yet it recorded a net income of -$24,737,000 and an EBITDA of -$24,744,000. The substantial gap between the minimal revenue and the significant net loss reveals a cost structure dominated by preclinical research expenses, personnel costs, and operational burn that far exceeds current sales generation. Free cash flow stands at -$11,346,000, indicating that the company is consuming cash to fund its development pipeline and has no current cash generation from operations. The gross margin is reported at 100.0%, suggesting that cost of goods sold is negligible at this preclinical stage, whereas the operating margin is -8491.0% and profit margin is 0.0%, highlighting severe operational losses relative to sales. The company holds $52.70M in cash against $2.45M in debt, creating a substantial liquidity buffer despite the negative earnings. The debt-to-equity ratio is 4.33, which suggests a leveraged balance sheet structure, yet the high cash position mitigates immediate solvency risks. Current ratio is 9.04, a figure that indicates robust short-term liquidity and the ability to cover obligations many times over with existing assets. Return on equity is -70.2% and return on assets is -37.0%, metrics that reveal the company is currently destroying value per share and per asset unit as it invests heavily in its preclinical pipeline before achieving profitability.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, while the forward P/E is -6.07, implying that the market expects earnings to remain negative or that valuation models are adjusting for the lack of historical profitability. The price-to-book ratio is 0.94, indicating that the market values the company at approximately 94% of its book value, which often reflects a market discount for preclinical biotech assets with unproven commercialization potential. The price-to-sales ratio is 202.66 and the EV/EBITDA is -0.43; these alternative metrics suggest that the market is pricing in significant growth expectations or strategic value beyond current financial performance. The 52-week high is $4.86 and the 52-week low is $0.56, placing the stock in a wide volatility range typical for small-cap biotechnology firms with speculative growth profiles. With a beta of 1.23, the stock exhibits price volatility that is 23% higher than the broader market, meaning it tends to amplify market movements rather than moving in lockstep with the S&P 500.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, reflecting the company's preclinical status where historical growth rates are not yet applicable for comparison. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm retains all available earnings to reinvest into its research and development activities rather than distributing income to shareholders. The absence of a dividend policy aligns with the standard lifecycle of preclinical biotechnology companies that must channel capital into asset development to achieve future commercialization milestones. The overall growth and income profile is characterized by zero current income distribution and undefined historical growth rates due to the lack of a commercial revenue base.